Biotechnology News and Research

RSS

TriReme Medical closes $17M Round D financing

TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

ArQule, Inc. today announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer (NSCLC) of non-squamous histology.

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics, Inc. today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

UH researchers receive grant to develop Blue Scale device to track heart failure

As more and more medical care is provided in the home, health specialists say it is critical for people to be able to monitor themselves and make informed judgments about their health. A group of researchers in the Abramson Center for the Future of Health at the University of Houston (UH) received a $250,000 pre-seed grant from the Texas Emerging Technology Fund (ETF) for a system that assesses cardiac function in the home and alerts the user to the need for intervention.

11 Oct 2010

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).

11 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

Non-GMO Day to raise awareness on genetically modified organisms in food supply

On Sunday, Oct. 10, Whole Foods Market and retailers across the country will celebrate Non-GMO Day to raise consumer awareness about the presence of genetically modified organisms (GMOs) in the food supply. Driven by the nonprofit Non-GMO Project, this Sunday's events are designed to send a wakeup call to consumers across the country.

8 Oct 2010

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Just as intense concentration allows a sharp mind to perform at its peak, a research institute that concentrates pre-eminent scientists from 11 academic departments can push back the frontiers of knowledge in a complex research area: the human brain.

8 Oct 2010

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes

8 Oct 2010

International scientific conference explores new approaches to prevent infectious diseases

Swine flu, cancer, bioterrorism and the latest trends in countermeasures to combat these life-threatening diseases and infections are among the topics to be discussed at the upcoming New Cells for New Vaccines V: Global Perspectives international scientific conference, on October 11-13 in Wilmington, Delaware, at the Hotel du Pont.

8 Oct 2010

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy that affects more than 400,000 patients who receive chemotherapy or radiation treatment in the U.S. each year. Current treatment options are very limited.

8 Oct 2010

ISCO to present data on Hepatocyte-like cells at ASSLD Annual Meeting

International Stem Cell Corporation, will present data on its progress toward producing human liver cells from immune-matched patient-specific parthenogenetic stem cells at The Liver Meeting, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (ASSLD), in Boston, MA from October 29 - November 2, 2010.

8 Oct 2010

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.

8 Oct 2010

Biotechnology News and Research

TriReme Medical closes $17M Round D financing

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics reports SGN-75 phase I clinical trial data

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

UH researchers receive grant to develop Blue Scale device to track heart failure

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

Non-GMO Day to raise awareness on genetically modified organisms in food supply

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

International scientific conference explores new approaches to prevent infectious diseases

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

ISCO to present data on Hepatocyte-like cells at ASSLD Annual Meeting

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News